LLY

807.28

+0.75%↑

UNH

516.88

-0.82%↓

NVO

135.68

+1.31%↑

MRK

131.09

+0.02%↑

ABBV

158.36

-0.72%↓

LLY

807.28

+0.75%↑

UNH

516.88

-0.82%↓

NVO

135.68

+1.31%↑

MRK

131.09

+0.02%↑

ABBV

158.36

-0.72%↓

LLY

807.28

+0.75%↑

UNH

516.88

-0.82%↓

NVO

135.68

+1.31%↑

MRK

131.09

+0.02%↑

ABBV

158.36

-0.72%↓

LLY

807.28

+0.75%↑

UNH

516.88

-0.82%↓

NVO

135.68

+1.31%↑

MRK

131.09

+0.02%↑

ABBV

158.36

-0.72%↓

LLY

807.28

+0.75%↑

UNH

516.88

-0.82%↓

NVO

135.68

+1.31%↑

MRK

131.09

+0.02%↑

ABBV

158.36

-0.72%↓

Search

Johnson and Johnson

Open

Sector Healthcare

149.61 -2.5

Overview

Share price change

24h

Current

Min

149.37

Max

152.49

Key metrics

By Trading Economics

Income

-22B

4B

Sales

-15M

21B

P/E

Sector Avg

32.629

23.904

EPS

2.71

Dividend yield

2.876

Profit margin

18.925

Employees

131,900

EBITDA

-386M

6.5B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+14.14 upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

2.88%

7.76%

Next Earnings

18 Jul 2024

Next Dividend date

4 Jun 2024

Market Stats

By TradingEconomics

Market Cap

4.7B

369B

Previous open

152.11

Previous close

149.61

News Sentiment

By Acuity

61%

39%

306 / 369 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

Johnson and Johnson Chart

Related News

16 May 2024, 12:07 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson Strikes $850 Million Deal to Boost Dermatology Portfolio

13 May 2024, 14:06 UTC

Acquisitions, Mergers, Takeovers

J&J to Sell Remaining Stake in Kenvue Spinoff

29 Apr 2024, 11:37 UTC

Major Market Movers

Addex Therapeutics Shares Plunge Premarket on Epilepsy Study Failure

24 Apr 2024, 23:16 UTC

Major Market Movers
Acquisitions, Mergers, Takeovers

Cidara Therapeutics Shares Surge 42% After Re-Acquiring Flu Asset

16 Apr 2024, 14:06 UTC

Earnings

Trending: Johnson & Johnson 1Q Adjust Earnings Beat Forecasts as Company Raises Dividend

16 Apr 2024, 11:01 UTC

Earnings

Johnson & Johnson 1Q Sales Rise on U.S. Growth, Narrows Adjusted EPS Outlook

21 May 2024, 20:25 UTC

Acquisitions, Mergers, Takeovers

Shockwave Medical: Waiting Period Under Hart-Scott-Rodino Act for Sale to Johnson & Johnson Expired Monday

17 May 2024, 03:56 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson Deal for Biotechnology Co Proteologix Includes Potential for Additional Milestone Payment

17 May 2024, 03:49 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson Agrees to Acquire Proteologix for $850M in Cash >JNJ

17 May 2024, 03:47 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson to Acquire Proteologix >JNJ

16 May 2024, 11:31 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson: Proteologix's Portfolio Includes PX128, a Bispecific Antibody Targeting IL-13 Plus TSLP >JNJ

16 May 2024, 11:31 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson: Acquisition Advances Dermatology Portfolio With Opportunity to Address Significant Unmet Need in Atopic Dermatitis >JNJ

16 May 2024, 11:31 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson to Acquire Proteologix for $850M in Cash, With Potential for Additonal Milestone Payments >JNJ

16 May 2024, 11:30 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson To Acquire Proteologix, Inc. To Lead In Atopic Dermatitis Treatment >JNJ

16 Apr 2024, 13:39 UTC

Hot Stocks

Stocks to Watch Tuesday: UnitedHealth, Tesla, J&J, Live Nation -- WSJ

16 Apr 2024, 12:57 UTC

Earnings

Bellwether Health Giant J&J Beats Earnings Calls, But Shares Dip On Light Sales -- IBD

16 Apr 2024, 11:13 UTC

Market Talk

Johnson & Johnson Extends Dividend Royalty -- Market Talk

16 Apr 2024, 10:32 UTC

Earnings

Johnson & Johnon's Q1 Profit Beats As Sales Fall Slightly Short Of Estimates -- MarketWatch

16 Apr 2024, 10:24 UTC

Earnings

Johnson & Johnson 1Q Adjusted Operational Sales Growth Excluding Covid-19 Vaccine 7.7% >JNJ

16 Apr 2024, 10:23 UTC

Earnings

Johnson & Johnson Raises Low Ends of 2024 Adjusted Operational EPS, Sales Growth Views >JNJ

16 Apr 2024, 10:23 UTC

Earnings

Johnson & Johnson Raises 2024 Operational Sales View to $88.7B-$89.1B >JNJ

16 Apr 2024, 10:22 UTC

Earnings

Johnson & Johnson Narrows 2024 Adjusted Operational Sales Growth View to 5.5%-6% >JNJ

16 Apr 2024, 10:22 UTC

Earnings

Johnson & Johnson Narrows 2024 Adjusted Operational EPS View to $10.60-$10.75 >JNJ

16 Apr 2024, 10:21 UTC

Earnings

Johnson & Johnson Narrows 2024 View To Adj EPS $10.57-Adj EPS $10.72 >JNJ

16 Apr 2024, 10:21 UTC

Earnings

Johnson & Johnson Narrows 2024 View To Sales $88B-$88.4B >JNJ

16 Apr 2024, 10:20 UTC

Earnings

Johnson & Johnson 1Q EPS $2.20 >JNJ

16 Apr 2024, 10:20 UTC

Earnings

Johnson & Johnson 1Q U.S. Sales $11.62B >JNJ

16 Apr 2024, 10:20 UTC

Earnings

Johnson & Johnson 1Q Worldwide MedTech Sales $7.82B >JNJ

16 Apr 2024, 10:20 UTC

Earnings

Johnson & Johnson 1Q International Sales $9.76B >JNJ

16 Apr 2024, 10:20 UTC

Earnings

Johnson & Johnson 1Q Adj EPS $2.71 >JNJ

Peer Comparison

Price change

Johnson and Johnson Forecast

Price Target

By TipRanks

14.14% upside

12 Months Forecast

Average 175.21 USD  14.14%

High 215 USD

Low 155 USD

Based on 15 Wall Street analysts offering 12 month price targets forJohnson and Johnson - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

15 ratings

8

Buy

7

Hold

0

Sell

Technical Score

By Trading Central

151.22 / 154.28Support & Resistance

Short Term

Weak Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Strong Bearish Evidence

Sentiment

By Acuity

306 / 369 Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Johnson and Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women’s health and wound care markets. The Pharmaceutical segment is focused on six immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism and pulmonary hypertension. The Medical Devices segment includes a range of products used in the interventional solutions, orthopedic, surgery, and vision fields.